Testing effectiveness (Phase 2)Study completedNCT05027074
What this trial is testing
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
Who this might be right for
End-Stage Renal DiseaseEnd-Stage Kidney DiseaseKidney Failure, Chronic
Merck Sharp & Dohme LLC 506